Our Story
From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years.
Timeline
Discover important moments throughout Ortho Clinical Diagnostic’s rich history of pioneering life-impacting advances.
Timeline
Discover important moments throughout Ortho Clinical Diagnostic’s rich history of pioneering life-impacting advances.
2022
QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
2021
Ortho Goes Public
Ortho began trading on The Nasdaq Global Select Market on January 28, 2021, under the symbol "OCDX".
Silver Stevie® Award for Sales & Customer Service
Ortho Care™ was recognized by the Stevie Awards for Exceptional Customer Service for the fifth years in a row.
Recognized by MedTech for COVID-19 Solutions
Ortho Clinical Diagnostics was recognized with MedTech’s 2020 Outstanding Contribution to the Bio/Med Industry Award for its COVID-19 Testing Solutions.
2020
Ortho Launches VITROS® COVID-19 Testing Solutions
Ortho launched the first high-volume antibody and antigen tests authorized by the U.S. Food and Drug Administration. The company’s COVID-19 solutions for mass-scale testing include two COVID-19 antibody tests — Total and IgG — both of which have FDA EUA and CE Mark, and an antigen test.
VITROS® XT Solutions Win Prestigious Global Edison Award for Innovation
Ortho was previously recognized with an Edison Award in 2018 for its VITROS NEPHROCHECK® Test1 and in 2017 for the ORTHO VISION® Platform.
ORTHO Optix™ Reader Completes Transfusion Medicine Portfolio
ORTHO Optix™ Reader becomes available in CE Mark countries.
VITROS® XT 3400 Chemistry System Enhances Its VITROS® XT Solutions
Solutions offer labs faster, more accurate results and trusted system reliability to ensure better patient outcomes.
2019
VITROS® XT Chemistry Product Slides
Multi-test technology allows labs to run two frequently ordered tests simultaneously on one slide.
VITROS® High Sensitivity Troponin I assay gets CE Mark
Helps more rapidly and accurately identify patients suffering from a heart attack.
2018
VITROS® XT 7600 Integrated System
Enables powerful data intelligence, operational improvements and other enhancements in the lab.
The Trailblazer Company of the Year
Honor by PM360 recognizes impact in the health care industry through innovation, social responsibility and talent development.
Gold-level Edison Award
Ortho’s VITROS® NEPHROCHECK® Test recognized with a gold-level Edison Award™ in the Best New Product Awards™ category
2017
ORTHO CONNECT™ V2.0 Middleware
Ortho Clinical Diagnostics receives CE Mark approval for ORTHO CONNECT™ V2.0 Middleware Solution
Edison Award™ for Outstanding Product Innovation
Ortho receives an Edison Award™ for Global Product Innovation, for its ORTHO VISION® Platform of fully automated analyzers, which test blood for compatibility before it is used in transfusions
China FDA approves ORTHO VISION Platform
The ORTHO VISION® Platform of fully automated blood analyzers for low-, mid- and high-volume transfusion medicine laboratories receives approval by the China Food and Drug Administration
2016
U.S. FDA clears ORTHO VISION Max
The U.S. FDA clears ORTHO VISION® Max Analyzer for High-Volume Transfusion Medicine Labs, making it commercially available in the U.S.
U.S. FDA clears VITROS Automation Solutions
The U.S. FDA clears VITROS® Automation Solutions for use with Ortho’s VITROS® Chemistry, Immunodiagnostics and Integrated Systems, allowing U.S. clinical laboratories to improve results throughout diagnostic testing
HIV Combo Test
Ortho Clinical Diagnostics receives CE Mark approval for its Immunodiagnostic HIV Combo Test, making it commercially available in those countries that accept CE Mark
2015
ORTHO VISION™ Analyzer available in U.S.
Ortho Clinical Diagnostics receives 510(k) clearance for ORTHO VISION™ Analyzer, making it commercially available in the United States. ORTHO VISION™ Analyzer automates the full range of immunohematology testing and helps improve the safety of blood transfusions by reducing the lab's reliance on manual methods
VITROS Automation Solutions released in EU and non-regulated markets
VITROS® Automation Solutions released in EU and non-regulated markets
ORTHO VISION® Max gets CE Mark
Ortho Clinical Diagnostics Receives CE Mark Clearance for ORTHO VISION® Max Analyzer for High-Volume Transfusion Medicine Labs, becoming commercially available in Europe and Japan
2014
The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson
The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson
Ortho Hosts 4th Annual Hospital C-Suite Summit in Singapore
Ortho Clinical Diagnostics Hosts 4th Annual Hospital C-Suite Summit in Singapore
Ortho Clinical Diagnostics receives CE Mark for ORTHO VISION
Ortho Clinical Diagnostics receives CE Mark for ORTHO VISION™ Analyzer, making it commercially available in Europe, Japan and Australia
2013
Ortho Clinical Diagnostics launches ORTHO Workstation
Ortho Clinical Diagnostics launches ORTHO™ Workstation, a next-generation semi-automated blood typing system
2011
Ortho Clinical Diagnostics launches the VITROS® 4600 Chemistry System
Ortho Clinical Diagnostics launches the VITROS® 4600 Chemistry System for mid- to high-volume laboratories
2009
Ortho Clinical Diagnostics launches the VITROS® 5600 Integrated System
Ortho Clinical Diagnostics launches the VITROS® 5600 Integrated System, which integrates clinical chemistry and immunoassay testing, and the VITROS® 3600 Immunodiagnostic System
2006
Ortho Clinical Diagnostics launches the first FDA-licensed test to screen blood donations for exposure to Chagas' disease
Ortho Clinical Diagnostics launches the first FDA-licensed test to screen blood donations for exposure to Chagas' disease
2005
Ortho Clinical Diagnostics launches the VITROS® 350 Chemistry System
Ortho Clinical Diagnostics launches the VITROS® 350 Chemistry System
2004
Ortho Clinical Diagnostics launches the VITROS® 5, 1 FS Chemistry System
Ortho Clinical Diagnostics launches the VITROS® 5, 1 FS Chemistry System, raising industry standards for ease-of-use, integrity of results, and operational efficiency
Ortho Clinical Diagnostics launches the VITROS® ECiQ Immunodiagnostic System and the ORTHO AutoVue® Innova System
Ortho Clinical Diagnostics launches the VITROS® ECiQ Immunodiagnostic System and the ORTHO AutoVue® Innova System
2003
Ortho Clinical Diagnostics launches ORTHO ProVue® Analyzer
Ortho Clinical Diagnostics launches ORTHO ProVue® Analyzer, the first fully automated immunohematology system for use with the ID-Micro Typing System™ (ID-MTS) Gel Test in North America
2002
Ortho Clinical Diagnostics acquires Micro Typing Systems of Pompano Beach
Ortho Clinical Diagnostics acquires Micro Typing Systems of Pompano Beach, Florida, the manufacturer of the ID-Micro Typing System™ (ID-MTS) used in hospitals and donor centers to help to ensure safe and effective blood transfusions
2001
Ortho Clinical Diagnostics becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests, on the VITROS® ECi Immunodiagnostic System
Ortho Clinical Diagnostics becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests, on the VITROS® ECi Immunodiagnostic System (for diagnostic use only; not for blood screening)
Ortho Clinical Diagnostics develops Ortho trak-C™
Ortho Clinical Diagnostics develops Ortho trak-C™, the world’s first branded “Total HCV Core Antigen” test designed to provide reliable measures of HCV viremia
2000
Ortho Clinical Diagnostics releases the HCV Core Antigen ELISA Test System
Ortho Clinical Diagnostics releases the HCV Core Antigen ELISA Test System—the first test commercially available for the direct detection in blood and plasma of HCV core antigen, a marker of early infection in hepatitis C–infected individuals
1999
Ortho Clinical Diagnostics becomes one of the first diagnostic industry suppliers to offer contracted implementation services
Ortho Clinical Diagnostics becomes one of the first diagnostic industry suppliers to offer contracted implementation services that can significantly reduce clinical laboratory costs through operational efficiencies and streamlined processes
1997
Ortho Clinical Diagnostics introduces the ORTHO AutoVue® System
Ortho Clinical Diagnostics introduces the ORTHO AutoVue® System, the first fully automated blood banking system in Europe
Ortho Clinical Diagnostics is formed from the merger of two Johnson & Johnson companies
Ortho Clinical Diagnostics is formed from the merger of two Johnson & Johnson companies: Ortho Diagnostic Systems, a worldwide leader in transfusion medicine reagents and instrument systems, and Johnson & Johnson Clinical Diagnostics (formerly a division of Eastman Kodak Co.), a worldwide leader in clinical laboratory systems
Ortho Products introduces VITROS ECi Immunodiagnostic System
Ortho Products introduces the most advanced immunodiagnostic system available in the industry, the VITROS® ECi Immunodiagnostic System
1994
Ortho Clinical Diagnostics introduces the Ortho Summit™ System
Ortho Clinical Diagnostics introduces the Ortho Summit™ System, the first fully automated blood and plasma screening system available in the US
1989
Ortho Products introduces the first test for the detection of antibodies to hepatitis C
Ortho Products introduces the first test for the detection of antibodies to hepatitis C
1978
Ortho Products introduces patented thin-film dry slide technology
Ortho Products introduces patented thin-film dry slide technology, once again revolutionizing the field of diagnostics by providing clinical professionals with the means to receive high-quality results quickly, cleanly, and economically
1947
Ortho Products develops the first blood bank anti-D test for the clinical market
Ortho Products develops the first blood bank anti-D test for the clinical market. This is a revolutionary advance in the burgeoning blood banking industry.
1944
Dr. Philip Levine joins Ortho Products
Dr. Philip Levine, a pioneer in the field of hematology, joins Ortho Products to continue his breakthrough research into the mechanics of the Rh system in human blood. This marks the beginning of the company's commitment to diagnostic medicine. Among Dr. Levine's many contributions is research that leads to the development of Rh immune globulin to protect Rh-negative women against isoimmunization, saving the lives of thousands of babies.
1939
Ortho Products, Inc., is formed
Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson